Anna Matilda Ekesbo Freisinger

Artiklar

Article: EUROPEAN JOURNAL OF PHARMACOLOGY. 2001;412(3):247-254
Effects of acute and repeated treatment with a novel dopamine D₂ receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys
Tahar AH; Ekesbo A; Grégoire L; Bangassoro E; Svensson KA; Tedroff J; Bédard PJ
Article: EUROPEAN JOURNAL OF PHARMACOLOGY. 2000;389(2-3):193-199
Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions
Ekesbo A; Andrén PE; Gunne LM; Sonesson C; Tedroff J
Article: NEUROLOGY. 1999;53(7):1605-1606
Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease
Tedroff J; Ekesbo A; Sonesson C; Waters N; Carlsson A
Article: ANNALS OF NEUROLOGY. 1999;46(3):359-365
Regulation of dopaminergic activity in early Parkinson's disease
Tedroff J; Ekesbo A; Rydin E; Långström B; Hagberg G
Article: NEUROPHARMACOLOGY. 1999;38(3):331-338
Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements of [¹¹C]SCH23390 and [¹¹C]raclopride binding in primate brains
Ekesbo A; Torstenson R; Hartvig P; Carlsson A; Sonesson C; Waters N; Tedroff J; Långström B
Article: NEUROLOGY. 1999;52(1):120-125
Dopamine autoreceptor function is lost in advanced Parkinson's disease
Ekesbo A; Rydin E; Torstenson R; Sydow O; Låengström B; Tedroff J
Article: NEUROREPORT. 1997;8(11):2567-2570
(-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease
Ekesbo A; Andren PE; Gunne LM; Tedroff J